How do patients receiving prescribed B12 injections for the treatment of PA perceive changes in treatment during the covid-19 pandemic? A UK based survey study

Abstract

Pernicious Anaemia (PA) is a chronic condition which is usually treated using B12 injections. Due to the pandemic many patients were prescribed an alternative oral B12 treatment. There is limited evidence that this is effective at managing symptoms of PA. The aim of this study was to document treatment changes across the UK and the impact on patient experience. An online survey explored how the treatment of PA has been managed during the early stages of the pandemic; responses were analysed for a sub-sample of participants receiving prescribed B12 injections and where changes in treatment applied (n=329) using content analysis. The most common reported change was suspension of injections, with oral B12 being offered as an alternative treatment. Patients were concerned about the long-term impact that changes would have on their condition management and many stated that they were dissatisfied with the level of care received. Those who were supported by healthcare providers to continue their usual treatment reported experiencing improved health and wellbeing. This study highlights the major impact of treatment changes on patient health outcomes, and the need to further support healthcare professionals with PA management during and beyond the pandemic.